Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Tidal Investments LLC

Tidal Investments LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 21.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 33,259 shares of the medical equipment provider's stock after buying an additional 5,855 shares during the quarter. Tidal Investments LLC's holdings in Zimmer Biomet were worth $3,513,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Trace Wealth Advisors LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $243,000. Studio Investment Management LLC grew its stake in Zimmer Biomet by 3.4% during the 4th quarter. Studio Investment Management LLC now owns 17,964 shares of the medical equipment provider's stock valued at $1,902,000 after purchasing an additional 591 shares in the last quarter. Snowden Capital Advisors LLC grew its stake in Zimmer Biomet by 84.5% during the 4th quarter. Snowden Capital Advisors LLC now owns 4,862 shares of the medical equipment provider's stock valued at $515,000 after purchasing an additional 2,227 shares in the last quarter. Siemens Fonds Invest GmbH grew its stake in Zimmer Biomet by 561.8% during the 4th quarter. Siemens Fonds Invest GmbH now owns 15,002 shares of the medical equipment provider's stock valued at $1,585,000 after purchasing an additional 12,735 shares in the last quarter. Finally, Royal Bank of Canada grew its stake in Zimmer Biomet by 67.3% during the 4th quarter. Royal Bank of Canada now owns 347,926 shares of the medical equipment provider's stock valued at $36,751,000 after purchasing an additional 139,959 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.39% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lowered their price objective on Zimmer Biomet from $128.00 to $105.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Morgan Stanley lowered their price objective on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Canaccord Genuity Group lowered their price objective on Zimmer Biomet from $115.00 to $101.00 and set a "hold" rating for the company in a research note on Monday, May 12th. Finally, Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $111.53.

Zimmer Biomet Trading Down 2.7%

Shares of NYSE ZBH opened at $92.73 on Thursday. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.92 and a 12-month high of $120.13. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The company has a market cap of $18.35 billion, a price-to-earnings ratio of 20.84, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The stock's 50 day simple moving average is $102.65 and its 200 day simple moving average is $105.59.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion for the quarter, compared to analysts' expectations of $1.89 billion. During the same period last year, the firm earned $1.94 EPS. The firm's revenue was up 1.1% compared to the same quarter last year. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.04%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet's dividend payout ratio is currently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.